Evaluation of extensive initial staging procedure in intermediate/high-risk melanoma patients

Journal of the European Academy of Dermatology and Venereology

Volumn 19, Issue 1, 2005, Pages 66-73

  Vereecken, Pierre ^a,b,d   Laporte, M ^a   Petein, M ^c   Steels, E ^a   Heenen, M ^a  

^a ERASME HOSPITAL   (Belgium)

^b CHU Andre Vesale   (Belgium)

^c INSTITUTE OF PATHOLOGY AND GENETICS   (Belgium)

^d NONE   (Belgium)

Author keywords

Melanoma; Staging

Indexed keywords

FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; MEDICAL ASSESSMENT; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY ANALYSIS; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE; WHOLE BODY SCINTISCANNING;

ADULT; AGED; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 13944259817     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2004.01130.x     Document Type: Article

References (52)

1. Greenlee RT, Murray T, Bolden S. Cancer statistics 2000. CA Cancer J Clin 2000; 50: 7-33.
2. Rigel DS, Carucci JA. Malignant melanoma: prevention, early detection and treatment in the 21st century. CA Cancer J Clin 2000; 50: 215-236.
3. Balch CM, Murad TM, Soong SJ et al. Tumor thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer 1979; 43: 883-888.
4. Sahin S, Rao B, Kopf AW et al. Predicting ten-year survival of patients with primary cutaneous melanoma: corroboration of a prognostic model. Cancer 1997; 80: 1426-1431.
5. Gamel JW, George SL, Edwards MJ, Seigler HF. The long-term clinical course of patients with cutaneous melanoma. Cancer 2002; 95(6): 1286-1293.
6. Ilmonen S, Asko-Seljavaara S, Kariniemi AL et al. Prognosis of primary melanoma. Scand J Surg 2002; 91(2): 166-171.
7. McMasters KM, Sondak VK, Lotze MT. Recent advances in melanoma staging and therapy. Ann Surg Oncol 1999; 6: 467-475.
8. Reintgen DR, Balch CM, Kirkwood J, Ross M. Recent advances in the care of the patient with malignant melanoma. Ann Surg 1997; 225: 1-14.
9. Horgan K, Hugues LE. Staging of melanoma. Clin Radiol 1993; 48: 297-300.
10. Buzaid AC, Sandler AB, Mani S. Role of computed tomography in the staging of melanoma. J Clin Oncol 1993; 11: 638-643.
11. Finck SJ, Giuliano AE, Morton DL. LDH and melanoma. Cancer 1983; 51(5): 840-843.
12. Karakousis CP, Velez A, Driscoll DL. Metastasectomy in malignant melanoma. Surgery 1994; 115: 295-302.
13. Wong JH, Skinner KA, Kim KA. The role of surgery in the treatment of non-regionally recurrent melanoma. Surgery 1993; 113: 389-394.
14. Rigo P, Paulus P, Kaschten B. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nuclear Med 1996; 23: 1641-1674.
15. Holder WD, White RL, Zuger JH, Easton EJ, Green FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998; 227(5): 764-771.
16. Morton DL, Wen DR, Wong JH. Technical details of intraoperative mapping for early stage melanoma. Arch Surg 1992; 127: 392-399.
17. Krag DN, Meijer SJ, Weaver DL. Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995; 130: 654-658.
18. Borgstein P, Meijer S. The sentinel node debate: historical perspective of lymphatic tumour spread and the emergence of the sentinel node concept. Eur J Surg Oncol 1998; 24: 85-89.
19. Slingluff CL Jr, Stidham KR, Ricci WM. Surgical management of regional lymph node in patients with melanoma. Experience with 4682 patients. Ann Surg 1994; 219: 120-130.
20. Stone CA, Goodacre TE. Surgical management of regional lymph nodes in primary cutaneous malignant melanoma. Br J Surg 1995; 82: 1015-1022.
21. Shapiro RL. Surgical approaches to malignant melanoma. Practical guidelines. Dermatol Clin 2002; 20(4): 681-699.
22. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American-Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19(16): 3635-3648.
23. DiFronzo LA, Wanek LA, Morton DL. Earlier diagnosis of second primary melanoma confirms the benefits of patient education and routine postoperative follow-up. Cancer 2001; 91(8): 1520-1524.
24. Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patient or physician based? Ann Surg 1995; 221: 566-571.
25. Dicker TJ, Kavanagh GM, Herd RM, Ahmad T. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol 1999; 140: 249-254.
26. Dummer R, Bosch U, Panizzon R, Bloch PH, Burg G. Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2001; 203: 75-80.
27. Negrier S, Fervers B, Bailly C et al. Clinical practice guidelines for diagnosis, treatment and follow-up of cutaneous melanoma. Bull Cancer 2000; 87(2): 173-182.
28. Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996; 23: 737-743.
29. Basseres N, Grob JJ, Richard MA et al. Cost effectiveness of surveillance of stage I melanoma: a retrospective appraisal based on a 10 year experience in a dermatology department in France. Dermatology 1995; 191: 199-203.
30. Hoffman U, Szedlak M, Rittgen W, Jung EG, Schadendorf D. Primary staging and follow-up in melanoma patients - monocenter evaluation of methods, costs and patient survival. Br J Cancer 2002; 87(2): 151-157.
31. Berman C, Reintgen D. Radiologic imaging in malignant melanoma: a review. Semin Surg Oncol 1993; 9: 232-238.
32. Kirkwood JM. Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies. Eur J Cancer 1998; 34 (Suppl. 3): s12-s17.
33. Thome SD, Loprinzi CL, Heldebrant MP. Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas. Mayo Clin Proc 2002; 77(9): 913-917.
34. Wagner JD, Schauwecker D, Davidson D et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999; 17: 1508-1515.
35. Crippa F, Leutner M, Belli F. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000; 41: 1491-1494.
36. Acland KM, Healy C, Calonje E et al. Comparison of PET scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001; 19 10): 2674-2678.
37. Mijnhout GS, Hoekstra OS, van Lingen A et al. How morphometric analysis of metastatic load predicts the (un) usefulness of PET scanning: the case of lymph node staging in melanoma. J Clin Pathol 2003; 56: 283-286.
38. Longo MI, Lazaro P, Bueno C, Carreras JL, Montz R. Fluorodeoxyglucose-positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients. Dermatol Surg 2003; 29: 245-248.
39. Morton DL. Sentinel lymphadenectomy for patients with clinical stage I melanoma. J Surg Oncol 1997; 66: 267-269.
40. Blocklet D, Donckier V, Vereecken P et al. Nondetection of sentinel lymph node with lymphoscintigraphy as a result of massive malignant invasion shown by positron emission tomography. Clin Nucl Med 2001; 26(12): 1013-1015.
41. Zartman GM, Thomas MR, Robinson WA. Metastatic disease in patients with newly diagnosed malignant melanomas. J Surg Oncol 1987; 35: 163-164.
42. Tremblay F, Louffi A, Shibata H, Meterissian S. Sentinel lymph-node biopsy for melanoma of the trunk and extremities: the McGill experience. Can J Surg 2001; 44(6): 428-431.
43. Landi G, Polverelli M, Moscatelli G et al. Sentinel lymph node biopsy in patients with primary cutaneous melanoma. study of 455 cases. J Eur Acad Dermatol Venereol 2000; 14: 35-45.
44. Clary BM, Brady MS, Lewis JJ, Coit DG. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg 2001; 233(2): 250-258.
45. Schmid-Wendtner MH, Baumert J, Wendtner CM, Plewig G, Volkenandt M. Risk of second primary malignancies in patients with cutaneous melanoma. Br J Dermatol 2001; 145(6): 981-985.
46. Bleicher RJ, Allegra DP, Nora DT et al. Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann Surg Oncol 2003; 10: 52-58.
47. Gerosa M, Nicolato A, Foroni R et al. Gamma knife radiosurgery for brain metastases: a primary therapeutic option. J Neurosurg 2002; 95 (Suppl. 5): 515-524.
48. Tyler DS, Onaitis M, Kherani A. Positron emission tomography scanning in malignant melanoma. Clinical utility in patients with stage III disease. Cancer 2000; 89: 1019-1025.
49. Prichard RS, Hill AD, Skehan SJ, O'Higgins NJ. Positron emission tomography for staging and management of malignant melanoma. Br J Surg 2002; 89(4): 389-396.
50. Chuang TY, Brashear R, Wagner JD, Farmer ER. Principles of evidence-based management using stage I-II melanoma as a model. Int J Dermatol 2002; 41: 721-728.
51. Garbe C, Paul A, Kohler-Spath H et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 2003; 21(3): 520-529.
52. Johnson TM, Bradford CR, Gruber SB, Sondak VK, Schwartz JL. Staging workup, sentinel node biopsy, and follow-up tests for melanoma. Update of current concepts. Arch Dermatol 2004; 140: 107-113.